GlassScriptPhysician profile
Trevor J Pearson
NPI 1639123516
$13,499.81
in general payments reported to CMS, 2019-2025
38 companies · $2,828 in 2025
The $2,828 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,474 · 2020: $352 · 2021: $776 · 2022: $1,734 · 2023: $1,966 · 2024: $4,371 · 2025: $2,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,031 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,030.99 |
| Education | $134.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $2,380.05 | 2024-2025 | Zenpep |
| Abbvie INC. | $2,233.06 | 2019-2025 | |
| Janssen Biotech, INC. | $1,519.11 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,032.58 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $981.34 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $815.24 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $632.30 | 2022-2025 | |
| Qol Medical, LLC | $530.36 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $476.80 | 2022-2025 | Dupixent |
| Celgene Corporation | $401.90 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $398.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $312.60 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $188.80 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $164.02 | 2019-2025 | Linzess |
| Intercept Pharmaceuticals, INC. | $136.53 | 2021-2025 | Ocaliva |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $129.24 | 2019-2024 | Dificid |
| Allergan, INC. | $127.27 | 2019 | |
| Celltrion USA INC. | $115.67 | 2024-2025 | Vegzelma, Zymfentra |
| Amgen INC. | $108.85 | 2021-2025 | Uplizna, Avsola, Amjevita |
| Ardelyx, INC. | $101.11 | 2023-2025 | Ibsrela |
| Pfizer INC. | $100.03 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $87.40 | 2019-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $82.94 | 2025 | Voquezna |
| Ucb, INC. | $81.14 | 2019-2020 | |
| Organon LLC | $56.56 | 2023-2025 | Hadlima |
| Nestle Healthcare Nutrition INC. | $47.26 | 2021-2023 | |
| Daiichi Sankyo INC. | $42.51 | 2022-2023 | Injectafer |
| Inari Medical, INC. | $31.68 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $22.17 | 2020-2025 | |
| Sandoz INC. | $21.80 | 2023 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.62 | 2023 | Cyltezo |
| Fresenius Kabi USA, LLC | $20.35 | 2023 | |
| Olympus America INC. | $19.46 | 2022 | |
| Conmed Corporation | $19.30 | 2019 | |
| Redhill Biopharma INC. | $17.05 | 2022 | |
| Welch Allyn | $16.90 | 2021 | |
| Shire North American Group INC | $14.16 | 2019 | |
| Baxter Healthcare | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.